Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Cancer cells share a common set of properties, including unlimited proliferation potential, self-sufficiency in terms of growth signals, and resistance to anti-proliferative and apoptotic cues. Acquiring these hallmarks involves changes in key oncogenes and non-oncogenes essential for cancer cell survival and prosperity, and is accompanied by the increased energy requirements of proliferating cells. Mitochondria occupy a central position in cell life and death with mitochondrial bioenergetics, biosynthesis, and signaling are critical for tumorigenesis. Voltage-dependent anion channel 1 (VDAC1) is situated in the mitochondrial outer membrane (OMM) and serving as a mitochondrial gatekeeper. VDAC1 allowing the transfer of metabolites, ions, Ca2+, ROS and cholesterol across the OMM and is a key player in mitochondrial-mediate apoptosis. Moreover, VDAC1 serves as a hub protein, interacting with diverse sets of proteins from the cytosol, endoplasmic reticulum, and mitochondria that together regulate metabolic and signaling pathways. The observation that VDAC1 is over-expressed in many cancers suggests that the protein may play a pivotal role in cancer cell survival. However, VDAC is also important in mitochondria-mediated apoptosis, mediating release of apoptotic proteins and interacting with anti-apoptotic proteins such as Bcl-2, Bcl-xL, and hexokinase, which are also highly expressed in many cancers. Strategically located in a “bottleneck” position, controlling metabolic homeostasis and apoptosis, VDAC1 thus represents an emerging target for anti-cancer drugs. This review presents an overview on VDAC1 as a multi-functional mitochondrial protein, regulating both cell life and death, and highlights the importance of the protein for cancer cell survival. We address recent results related to the mechanisms of VDAC1-mediated apoptosis and the potential of associated proteins to modulate of VDAC1 activity, with the aim of developing VDAC1-based strategies to attack the altered metabolism and/or to activate apoptosis of cancer cells. These strategies include siRNA able to impair energy and metabolic homeostasis, leading to arrested cancer cell growth, inhibited tumor growth and reversed oncogenic properties, as well as VDAC1-based peptides that interact with anti-apoptotic proteins to induce apoptosis. Finally, we discuss the potential therapeutic benefits of treatments and drugs leading to enhanced VDAC1 expression or targeting VDAC1 to induce apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“Cancer cells exhibit significant metabolic alterations with respect to several critical substrates, including important changes in the metabolism of both glucose and glutamine that require plasticity of the metabolic machinery (107, 108).”
BackgroundThe Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 1×
“The intrinsic pathway is regulated by members of the B-cell lymphoma 2 (Bcl-2) family of proteins (125), and by the inhibitor of apoptosis protein (IAP) family of proteins (126).”
BackgroundMitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · cited 6×
“The AIF released is translocated to the nucleus, leading to chromatin condensation and DNA fragmentation (124).”
BackgroundInfluentialOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280 · cited 1×
“However, in knockout experiments performed in mice, even mitochondria examined from cells lacking some but not all ANT isoforms (148, 149), or VDAC1 (150) showed PTP formation.”
BackgroundShimizu, S., Narita, M., Tsujimoto, Y., & Tsujimoto, Y. (1999) · Nature · doi:10.1038/20959 · Cited by 2,178 · cited 3×
“Evidence supporting the activity of VDAC1 in apoptosis includes (a) Cyto c release, cell death, and Bax–VDAC1 interaction were all inhibited by anti-VDAC1 antibodies (135–137); (b) HK-I and HK-II interacting with VDAC1 inhibited staurosporine (STS)-induced Cyto c release and apoptosis in native but not mutated VDAC1-e…”
BackgroundMitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., et al. (2007) · Nature · doi:10.1038/nature05859 · Cited by 1,631
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“Aβ also affects mitochondrial respiration (297) and activates Cyto c release, resulting in apoptosis (298).”
BackgroundThe ADP/ATP translocator is not essential for the mitochondrial permeability transition pore
Kokoszka, J. E., Waymire, K. G., Levy, S. E., Sligh, J. E., Cai, J., Jones, D. P., MacGregor, G. R., & Wallace, D. C. (2004) · Nature · doi:10.1038/nature02229 · Cited by 1,086 · cited 1×
“However, in knockout experiments performed in mice, even mitochondria examined from cells lacking some but not all ANT isoforms (148, 149), or VDAC1 (150) showed PTP formation.”
BackgroundTumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085
Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
Wilson, J. E. (2003) · Journal of Experimental Biology · doi:10.1242/jeb.00241 · Cited by 1,085
Mitochondria in neuroplasticity and neurological disorders
Mattson, M. P., Gleichmann, M., & Cheng, A. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.010 · Cited by 1,081 · cited 1×
“Recent studies have shown that such disorders share characteristics of mitochondria-mediated apoptotic death (293).”
BackgroundTrachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.009 · Cited by 1,080
VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis
Cheng, E. H.-Y., Sheiko, T. V., Fisher, J. K., Craigen, W. J., & Korsmeyer, S. J. (2003) · Science · doi:10.1126/science.1083995 · Cited by 852 · cited 1×
“By contrast, VDAC2 is anti-apoptotic (27), is crucial for Bak recruitment (28), and is a critical inhibitor of Bak-mediated apoptosis (29).”
BackgroundHan, D., Antunes, F., Canali, R., Rettori, D., & Cadenas, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210269200 · Cited by 711 · cited 2×
“Evidence supporting the activity of VDAC1 in apoptosis includes (a) Cyto c release, cell death, and Bax–VDAC1 interaction were all inhibited by anti-VDAC1 antibodies (135–137); (b) HK-I and HK-II interacting with VDAC1 inhibited staurosporine (STS)-induced Cyto c release and apoptosis in native but not mutated VDAC1-e…”
BackgroundMcEnery, M. W., Snowman, A. M., Trifiletti, R. R., & Snyder, S. H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3170 · Cited by 708
Solution structure of the integral human membrane protein VDAC-1 in detergent micelles
Hiller, S., Garces, R. G., Malia, T. J., Orekhov, V. Y., Colombini, M., & Wagner, G. (2008) · Science · doi:10.1126/science.1161302 · Cited by 667
Structure of the human voltage-dependent anion channel
Bayrhuber, M., Meins, T., Habeck, M., Becker, S., Giller, K., Villinger, S., Vonrhein, C., Griesinger, C., Zweckstetter, M., & Zeth, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808115105 · Cited by 588
Redox regulation of mitochondrial function
Handy, D. E., & Loscalzo, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4123 · Cited by 588 · cited 1×
“While ROS promote tumorigenicity through signaling, they can also selectively kill a number of cancer cell lines (102) as well as normal cells, attacking DNA, lipids, and proteins (103).”
BackgroundMyocytes Die by Multiple Mechanisms in Failing Human Hearts
Kostin, S., Pool, L., Elsässer, A., Hein, S., Drexler, H. C. A., Arnon, E., Hayakawa, Y., Zimmermann, R., Bauer, E., Klövekorn, W.-P., et al. (2003) · Circulation Research · doi:10.1161/01.res.0000067471.95890.5c · Cited by 564 · cited 1×
“Inhibiting apoptosis at an early stage, such as VDAC1 oligomerization, may be an effective approach to block or slow apoptosis in neurodegenerative disorders (193) and various cardiovascular diseases, where there is enhanced apoptosis (194, 195).”
BackgroundMadesh, M., & Hajnóczky, G. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105057 · Cited by 538 · cited 1×
“Evidence supporting the activity of VDAC1 in apoptosis includes (a) Cyto c release, cell death, and Bax–VDAC1 interaction were all inhibited by anti-VDAC1 antibodies (135–137); (b) HK-I and HK-II interacting with VDAC1 inhibited staurosporine (STS)-induced Cyto c release and apoptosis in native but not mutated VDAC1-e…”
AZOULAY-ZOHAR, H., ISRAELSON, A., ABU-HAMAD, S., & SHOSHAN-BARMATZ, V. (2004) · Biochemical Journal · doi:10.1042/bj20031465 · Cited by 408
Self-citationRone, M. B., Fan, J., & Papadopoulos, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.03.001 · Cited by 399
GINCEL, D., ZAID, H., & SHOSHAN-BARMATZ, V. (2001) · Biochemical Journal · doi:10.1042/bj3580147 · Cited by 396
Self-citationSurvivin and IAP proteins in cell-death mechanisms
Altieri, D. C. (2010) · Biochemical Journal · doi:10.1042/bj20100814 · Cited by 376
Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach
Sultana, R., Poon, H. F., Cai, J., Pierce, W. M., Merchant, M., Klein, J. B., Markesbery, W. R., & Butterfield, D. A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.10.004 · Cited by 364 · cited 1×
“Finally, an increase in nitrated VDAC1 in AD was reported, reflecting oxidative damage to VDAC (304), and possibly affecting cell energy and metabolite homeostasis (305).”
BackgroundAbu-Hamad, S., Zaid, H., Israelson, A., Nahon, E., & Shoshan-Barmatz, V. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708216200 · Cited by 278
Lee, K., Kerner, J., & Hoppel, C. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228692 · Cited by 254 · cited 2×
“Finally, in rat liver mitochondria, VDAC1 is proposed as part of a complex mediating the transport of fatty acids through the OMM (84).”
BackgroundAbu-Hamad, S., Arbel, N., Calo, D., Arzoine, L., Israelson, A., Keinan, N., Ben-Romano, R., Friedman, O., & Shoshan-Barmatz, V. (2009) · Journal of Cell Science · doi:10.1242/jcs.040188 · Cited by 226 · cited 14×
“Both HK-II and HK-I bind to mitochondria (16, 17, 81, 133) and possess the hydrophobic N-terminal domain necessary for binding to mitochondria.”
BackgroundInfluentialSelf-citationSkalsky, R. L., & Cullen, B. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024248 · Cited by 170 · cited 4×
“Other studies from our group (271) using a GBM xenograft mouse model showed that upon VDAC1 depletion, several pro-apoptotic proteins were overexpressed yet apoptosis was not induced.”
BackgroundInfluentialArbel, N., & Shoshan-Barmatz, V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.082990 · Cited by 168 · cited 12×
“N-Ter-Antp peptide interacted with HK, Bcl-2, and Bcl-xL and inhibited their anti-apoptotic effects (16–20, 133).”
BackgroundInfluentialShi, Y., Chen, J., Weng, C., Chen, R., Zheng, Y., Chen, Q., & Tang, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00871-4 · Cited by 158
Ben-Hail, D., Begas-Shvartz, R., Shalev, M., Shteinfer-Kuzmine, A., Gruzman, A., Reina, S., De Pinto, V., & Shoshan-Barmatz, V. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744284 · Cited by 158 · cited 3×
“Evidence supporting the activity of VDAC1 in apoptosis includes (a) Cyto c release, cell death, and Bax–VDAC1 interaction were all inhibited by anti-VDAC1 antibodies (135–137); (b) HK-I and HK-II interacting with VDAC1 inhibited staurosporine (STS)-induced Cyto c release and apoptosis in native but not mutated VDAC1-e…”
BackgroundSelf-citationReddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
Smilansky, A., Dangoor, L., Nakdimon, I., Ben-Hail, D., Mizrachi, D., & Shoshan-Barmatz, V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.691493 · Cited by 143 · cited 3×
“VDAC1 was shown to participate in Aβ-induced toxicity (45, 301, 302) where Aβ–VDAC1 interactions are toxic to AD-affected neurons (303) and VDAC1 interactions with Aβ and phosphorylated Tau lead to mitochondrial dysfunction (302).”
BackgroundSelf-citationA proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431
Castagna, A., Antonioli, P., Astner, H., Hamdan, M., Righetti, S. C., Perego, P., Zunino, F., & Righetti, P. G. (2004) · PROTEOMICS · doi:10.1002/pmic.200400835 · Cited by 139
Head, S. A., Shi, W., Zhao, L., Gorshkov, K., Pasunooti, K., Chen, Y., Deng, Z., Li, R.-J., Shim, J. S., Tan, W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512867112 · Cited by 111 · cited 1×
“Another connection between VDAC1 and cell energy signaling was demonstrated in recent studies showing that VDAC1 is a direct target of the anti-fungal agent, itraconazole, and that VDAC1 is a key mediator of the inhibition of mTOR and endothelial cell proliferation by the AMPK signaling pathway (270, 272).”
BackgroundGeula, S., Ben-Hail, D., & Shoshan-Barmatz, V. (2012) · Biochemical Journal · doi:10.1042/bj20112079 · Cited by 105
Self-citationStructure-based Analysis of VDAC1 Protein
Geula, S., Naveed, H., Liang, J., & Shoshan-Barmatz, V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.268920 · Cited by 97
Self-citationVoltage-dependant anion channels: novel insights into isoform function through genetic models
Raghavan, A., Sheiko, T., Graham, B. H., & Craigen, W. J. (2012) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2011.10.019 · Cited by 92
Mitochondrial apoptosis without VDAC
Galluzzi, L., & Kroemer, G. (2007) · Nature Cell Biology · doi:10.1038/ncb0507-487 · Cited by 91 · cited 7×
“These models include (a) VDAC1 closure and outer mitochondrial membrane (OMM) rupture serving as the Cyto c release pathway—prolonged VDAC1 closure leads to mitochondrial matrix swelling and OMM rupture, resulting in the appearance of a non-specific release pathway for apoptogenic proteins; (b) a permeability transiti…”
BackgroundInfluentialVDAC1-interacting anion transport inhibitors inhibit VDAC1 oligomerization and apoptosis
Ben-Hail, D., & Shoshan-Barmatz, V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.002 · Cited by 80
Self-citationAghazadeh, Y., Rone, M. B., Blonder, J., Ye, X., Veenstra, T. D., Hales, D. B., Culty, M., & Papadopoulos, V. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.339580 · Cited by 46 · cited 1×
“In addition to VDAC1, the transduceosome also includes the OMM high-affinity cholesterol-binding protein translocator protein (TSPO) and the steroidogenic acute regulatory protein (79) (Figure 2).”
Background
Cited by
VDAC1, mitochondrial dysfunction, and Alzheimer’s disease
Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286
Self-citationAutophagy and mitophagy in cancer metabolic remodelling
Ferro, F., Servais, S., Besson, P., Roger, S., Dumas, J.-F., & Brisson, L. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.029 · Cited by 281
Zhang, E., Mohammed Al-Amily, I., Mohammed, S., Luan, C., Asplund, O., Ahmed, M., Ye, Y., Ben-Hail, D., Soni, A., Vishnu, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.008 · Cited by 171
“VDAC1 is a target in cancer therapy (Shoshan-Barmatz et al., 2017) and”
BackgroundER-mitochondria interactions: Both strength and weakness within cancer cells
Doghman-Bouguerra, M., & Lalli, E. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.01.009 · Cited by 94
Metadata
- Authors
- Shoshan-Barmatz, V., Krelin, Y., Shteinfer-Kuzmine, A., & Arif, T.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-31
- Volume
- 7
- Pages
- 154-154
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2732956904
- Cited by
- 133
- References
- 46
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.